### Antiretroviral Impact on Neurocognitive and Sleep Profile in HIV-Infected children due to vertical transmission.

### NeuroCoRISpeS cohort

<u>Gonzalez Tomé, MI (1)</u>; Garcia- Navarro C(2); Jimenez de Ory S(3); Zamora B (2), Saavedra J(3), Falcón D(4), Cuéllar I (1), Mellado MJ (5), Ruiz Moreno F(6).

1Sección de Infecciosas Pediátricas . Hospital 12 de Octubre; 2 Neuropsicología Infantil, Hospital 12 de Octubre; 3 Seccion de Infecciosas Pediátricas , Hospital Gregorio Marañón;4 Seccion de Infecciosas Pediátricas, Hospital Virgen del Rocío, 5 Seccion de Infecciosas Pediátricas ,Hospital La Paz-Carlos III,6 Seccion de Infecciosas Pediátricas ,Hospital Carlos Haya. <u>In the name of NeuroCoRIspeS-Madrid Cohort</u>

## Introduction

- Children with HIV infection due to vertical transmission have improved their quality of life. However, new challenges have emerged.
- **NeuroCoRIspeS cohort** started in 2007 to study psychosocial, emotional and behavioural profile.
- About educational achievement, we observed that most of children (90%) attended school but nearly 60% of them had been held back one or more school years.
  - These results led us to study neurocognitive profile of our cohort.



#### Enfermedades Infecciosas y Microbiología Clínica

Microbiolog

www.elsevier.es/elm

Original

Aspectos psicosociales en una cohorte de adolescentes con infección por el virus de la inmunodeficiencia humana por transmisión vertical. NeuroCoRISpeS\*

Cristina García-Navarro<sup>a,f</sup>, Isabel García<sup>b</sup>, Gabriela Medín<sup>c</sup>, José Tomás Ramos-Amador<sup>d</sup>, Marisa Navarro-Gómez<sup>c</sup>, M. José Mellado-Peña<sup>b</sup>, M.I. de José Gómez<sup>e</sup>, Marisol Cortés<sup>d</sup>, Berta Zamora Crespo<sup>f</sup>, M. Angeles Muñoz-Fernandez<sup>g</sup>, Daniel Blázquez Gamero<sup>a</sup> y M. Isabel González-Tomé<sup>a,\*</sup>

# **Objectives / Population**

#### **Objectives:**

- To determine neurocognitive profile and possible risk factors.
  - (see poster-> García Navarro, C; et al : "Neurocognitive profile in HIV vertical transmission children").
- To determine whether ART could have an impact on neurocognitive profile and sleep quality, both essential for daily functioning.

#### **Population:**

 Patients between 4 to 23 years old with HIV infection due to vertical transmission were included. These patients belong to spanish national cohort (CoRISpeS-Madrid Cohort).



SCREENING NEUROCOGNITIVO						
(Duración: 1,30 hora)						
	G1: 4-6 año	G2: 7-12 años	G3 y G4: 13-18 y 19-21 años			
F. generales Cognitivas	K-BIT Kaufman: IC IF CI	K-BIT Kaufman: IC IF CI	K-BIT Kaufman: IC IF CI			
F unciones Atencionales	<u>Sostenida:</u> Claves-CUMANIN	<u>Retención:</u> Dígitos WISC-IV <u>Sostenida:</u> Claves WISC-IV <u>C. Atencional:</u> Stroop/Luria	<u>Retención:</u> Dígitos WISC-IV <u>Sostenida:</u> Claves- CUMANIN <u>Control Atencional</u> LURIA-DNA			
F. Visuo (perceptivas, motoras y espaciales)	Figura de REY	Figura de REY	Figura de REY			
F unciones Mnésicas	M.Espacial Figura de REY M.Iconica CUMANIN	<u>M.Espacial:</u> Figura de REY <u>M.Inmediata</u> : Luria DNI/ Luria DNA	<u>M.Espacial</u> : Figura de REY <u>M.Inmediata</u> : Luria DNI/ Luria DNA			
Funciones Ejecutivas		Fluidez Verbal (ENFEN) Senderos (ENFEN)	Fluidez Verbal (PMR) Trail Making Test			
PedsQL Pittsburgh Sleep Quality Index (PSQI) + Al adverse effects.			<ul> <li>Attention</li> <li>Visuoconstructive skills</li> <li>Executive function</li> <li>Memory</li> </ul>			



# Sample description

N: 79 patients

#### Sex:

- 65.8% Females

#### Median age:

- At the beginning of the study: 16 years (5 23)
- At diagnosis: 0.48 years (0-11.0)

### Ethnicity:

- Caucasian: 62.3%
- South American: 10.1%
- Sub-saharan African: 10.1%
- Others: 10.5%

## **Clinical and Immunovirological situation**

AIDS category: 18 patients (23.4%) HIV-Encephalopathy: 9 patients (11.4%)

CDC clinical categ.%

Median CD4 nadir: 15.0% (0.76, 40) (360,5 cells/mm3 (13, 1342))



Current immunovirological situation: Median CD4: 688 (43, 993) Median CD4/CD8: 0.9 (0.3, 2.4) Viral load <50cop/ml: 64 patients, (86.5%)

Most common ARV combination: 2NRTI+PI 65.3% 2NRTI+ 1 NNRTI 41.3%

Time of treatment with any ART: 11.8 years (0.5-20.6) Time of HAART: 11 years (0.5-17.7)

Good adherence: 85.4%

## Specific neurocognitive skills profile



Attentional and executive (phonemic fluency) capabilities are the most frequently affected.

# Intellectual skills performance



- Crystallized Intell. < Fluid Intell.
- Great IQ percentaje non valid.

## Performance in attentional task related to ART

Attention / Retention 100 80 62,5 ■ ≥ Average 55,3 -1DT 50 50 -2DT 42.4 37.5 35,7 35.6 33,3 23,7 22 21.1 \* p < 0,05 16.7 14,3 0 NRTIS NNRTIS Pls Others EFV

Relationship between attentional tasks performance (Digit retention and Digit-symbol test) and ARV drugs prescribed at the assessment time



# Fluid I. and Cristalized I. and immunovirological situation

	Normal Cristalized Intell.	Normal Fluid Intel	I.
VL < 50 cop/ml	59%	87%	P>0.05
VL> 50 cop/ml	33%	67%	P>0.05

FLUID INTELL.	CD4 nadir cel/mm3 (median)
≥ 1SD	193
-1SD-MEDIAN	262
MEDIAN	391
P*	0.054

#### \* Kruskall Wallis

## Patients on EFV- based regimen versus another ARV and sleep disturbances



Percentage of patients who presented several disturbances in PSQI depending on the intake or not of EFV. Disturbances included are ranged from mild to severe. Poorer quality mainly in sleep latency (p=0.001) and sleep efficiency (p=0.045) were found in these patients who were taking EFV



## **Conclusions**

- In our patients neurocognitive deficits affects principally to attentional and executive abilities
  - IQ Composure doesn't reflect their intellectual capacities.
- Regarding ART, NNRTI seems to be involved in attencion.
  - CD4 nadir could be related to FI which is linked to innate potential
- Sleep disturbances and poor sleep quality are more common in patients on EFV

The main limitation of our study is the small size of the sample

We consider that more patients and a control group have to included to confirm these results.

# Acknowledgement

### Members of the Spanish Cohort of Pediatric HIV-Infected Patients (CoRISpe) group included in NeuroCoRISpeS&Madrid Cohort:

#### Medical team:

Pablo Rojo, Mª Isabel González-Tomé, Daniel Blázquez Gamero, Jesús Ruiz Contreras (*Hospital 12 de Octubre*); María José Mellado Peña, María Isabel de José Gómez, Luis Escosa, Miluca García Hortelano (*Hospital La Paz-Carlos III*); José Tomas Ramos Amador, Sara Guillen Martín (*Hospital Universitario de Getafe*); (*Hospital Carlos III*); María Luisa Navarro Gómez, Jesús Saavedra Lozano, Mar Santos, María Dolores Gurbindo Pérez, Santiago Jiménez de Ory, María Ángeles Muñoz Fernández, Talía Sanz Costa (*Hospital Universitario Gregorio Marañón*); Jorge Martínez Pérez (*Hospital Niño Jesús*); Cristina Calvo Rey (*Hospital Severo Ochoa*); Miguel Ángel Roa Francia (*Hospital de Móstoles*); David Moreno, Esmeralda Núñez (*Hospital Carlos Haya*); César Gavilán (*Hospital San Juan de Alicante*); Carmen López, Francisca Pelechano (*Hospital de Castellón*); Olaf Neth, Dolores Falcón, Mª Dolores Lanzarote (*Hospital Virgen del Rocío*);); Mª Carmen Otero, Ana Ortí, Amparo Pérez (*Hospital La Fe*)

#### Neuropsychological team: Cristina García-Navarro, Berta Zamora Crespo,

Psychological team: Isabel Avilés, Marisol Cortés, María Sierra, Francisca Ruiz, Gabriela Medín, Ramón Ferrando.

Proyects: Mutua Madrileña 2012/0077, Gilead Fellowship 2013/0071. María Isabel González-Tomé (PI) ,CoRISpe (RED RIS RD06/0006/0035 y RD06/0006/0021): coordinators Marisa Navarro Gómez, Mª Isabel González-Tomé; Cohorte de Madrid (FIPSE 3608229/09) IP: José Tomás Ramos Amador.

Contact: cristinagcn@gmail.com, maribelgt73@gmail.com